These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16945746)

  • 1. Regional heterogeneity of resting perfusion in hypertrophic cardiomyopathy is related to delayed contrast enhancement but not to systolic function: a PET and MRI study.
    Knaapen P; van Dockum WG; Götte MJ; Broeze KA; Kuijer JP; Zwanenburg JJ; Marcus JT; Kok WE; van Rossum AC; Lammertsma AA; Visser FC
    J Nucl Cardiol; 2006 Sep; 13(5):660-7. PubMed ID: 16945746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed contrast enhancement and perfusable tissue index in hypertrophic cardiomyopathy: comparison between cardiac MRI and PET.
    Knaapen P; van Dockum WG; Bondarenko O; Kok WE; Götte MJ; Boellaard R; Beek AM; Visser CA; van Rossum AC; Lammertsma AA; Visser FC
    J Nucl Med; 2005 Jun; 46(6):923-9. PubMed ID: 15937301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does myocardial fibrosis hinder contractile function and perfusion in idiopathic dilated cardiomyopathy? PET and MR imaging study.
    Knaapen P; Götte MJ; Paulus WJ; Zwanenburg JJ; Dijkmans PA; Boellaard R; Marcus JT; Twisk JW; Visser CA; van Rossum AC; Lammertsma AA; Visser FC
    Radiology; 2006 Aug; 240(2):380-8. PubMed ID: 16864667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional systolic function, myocardial blood flow and glucose uptake at rest in hypertrophic cardiomyopathy.
    Perrone-Filardi P; Bacharach SL; Dilsizian V; Panza JA; Maurea S; Bonow RO
    Am J Cardiol; 1993 Jul; 72(2):199-204. PubMed ID: 8328384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy.
    Knaapen P; Germans T; Camici PG; Rimoldi OE; ten Cate FJ; ten Berg JM; Dijkmans PA; Boellaard R; van Dockum WG; Götte MJ; Twisk JW; van Rossum AC; Lammertsma AA; Visser FC
    Am J Physiol Heart Circ Physiol; 2008 Feb; 294(2):H986-93. PubMed ID: 18156203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of intravascular and extravascular mechanisms of myocardial perfusion abnormalities in obstructive hypertrophic cardiomyopathy by myocardial contrast echocardiography.
    Soliman OI; Knaapen P; Geleijnse ML; Dijkmans PA; Anwar AM; Nemes A; Michels M; Vletter WB; Lammertsma AA; ten Cate FJ
    Heart; 2007 Oct; 93(10):1204-12. PubMed ID: 17488767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal.
    Castagnoli H; Ferrantini C; Coppini R; Passeri A; Baldini K; Berti V; Cecchi F; Olivotto I; Sciagrà R
    Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2413-2422. PubMed ID: 27527796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation of coronary microvascular dysfunction in hypertrophic cardiomyopathy to contractile dysfunction independent from myocardial injury.
    Timmer SA; Germans T; Götte MJ; Rüssel IK; Lubberink M; Ten Berg JM; Ten Cate FJ; Lammertsma AA; Knaapen P; van Rossum AC
    Am J Cardiol; 2011 May; 107(10):1522-8. PubMed ID: 21377644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional heterogeneity of function in hypertrophic cardiomyopathy.
    Kramer CM; Reichek N; Ferrari VA; Theobald T; Dawson J; Axel L
    Circulation; 1994 Jul; 90(1):186-94. PubMed ID: 8025995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy.
    Sotgia B; Sciagrà R; Olivotto I; Casolo G; Rega L; Betti I; Pupi A; Camici PG; Cecchi F
    J Nucl Med; 2008 Jul; 49(7):1090-6. PubMed ID: 18552138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed enhancement in hypertrophic cardiomyopathy: comparison with myocardial tagging MRI.
    Kim YJ; Choi BW; Hur J; Lee HJ; Seo JS; Kim TH; Choe KO; Ha JW
    J Magn Reson Imaging; 2008 May; 27(5):1054-60. PubMed ID: 18425835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed hyper-enhancement of myocardium in hypertrophic cardiomyopathy with asymmetrical septal hypertrophy: comparison with global and regional cardiac MR imaging appearances.
    Amano Y; Takayama M; Takahama K; Kumazaki T
    J Magn Reson Imaging; 2004 Oct; 20(4):595-600. PubMed ID: 15390225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial blood flow and fibrosis in hypertrophic cardiomyopathy.
    Aquaro GD; Todiere G; Barison A; Strata E; Marzilli M; Pingitore A; Lombardi M
    J Card Fail; 2011 May; 17(5):384-91. PubMed ID: 21549295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a
    Sciagrà R; Calabretta R; Cipollini F; Passeri A; Castello A; Cecchi F; Olivotto I; Pupi A
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):866-875. PubMed ID: 28050630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy.
    Bravo PE; Pinheiro A; Higuchi T; Rischpler C; Merrill J; Santaularia-Tomas M; Abraham MR; Wahl RL; Abraham TP; Bengel FM
    J Nucl Med; 2012 Mar; 53(3):407-14. PubMed ID: 22315440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resting myocardial blood flow is impaired in hibernating myocardium: a magnetic resonance study of quantitative perfusion assessment.
    Selvanayagam JB; Jerosch-Herold M; Porto I; Sheridan D; Cheng AS; Petersen SE; Searle N; Channon KM; Banning AP; Neubauer S
    Circulation; 2005 Nov; 112(21):3289-96. PubMed ID: 16286587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitral annular plane systolic excursion is an easy tool for fibrosis detection by late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
    Doesch C; Sperb A; Sudarski S; Lossnitzer D; Rudic B; Tülümen E; Heggemann F; Schimpf R; Schoenberg SO; Borggrefe M; Papavassiliu T
    Arch Cardiovasc Dis; 2015; 108(6-7):356-66. PubMed ID: 25863428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stress Myocardial Blood Flow Heterogeneity Is a Positron Emission Tomography Biomarker of Ventricular Arrhythmias in Patients With Hypertrophic Cardiomyopathy.
    Lu DY; Yalçin H; Yalçin F; Zhao M; Sivalokanathan S; Valenta I; Tahari A; Pomper MG; Abraham TP; Schindler TH; Abraham MR
    Am J Cardiol; 2018 May; 121(9):1081-1089. PubMed ID: 29678336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy.
    Olivotto I; Cecchi F; Gistri R; Lorenzoni R; Chiriatti G; Girolami F; Torricelli F; Camici PG
    J Am Coll Cardiol; 2006 Mar; 47(5):1043-8. PubMed ID: 16516091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of pixel-wise parametric mapping of myocardial blood flow with ¹³NH₃ PET in patients with hypertrophic cardiomyopathy.
    Sciagrà R; Passeri A; Cipollini F; Castagnoli H; Olivotto I; Burger C; Cecchi F; Pupi A
    Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1581-8. PubMed ID: 26121929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.